<p>Medpace Holdings, Inc. (NASDAQ:MEDP - 获取免费报告) 的股价在周四因内部人士出售股票而下跌了 3.7%。该股最低交易价为 530.96 美元，最后交易价为 554.93 美元。在交易中，共成交 157,218 股，较 408,083 股的平均交易量下降了 61%。该股此前收盘价为 576.49 美元。</p>
<ul>
<li>Medpace 股票能否保持这种速度？</li>
</ul>
<p>具体来说，首席执行官 August J. Troendle 在 12 月 1 日（星期一）出售了 23,178 股公司的股票。股票以 593.25 美元的平均价格出售，总价值为 13,750,348.50 美元。出售完成后，首席执行官在公司持有 652,550 股，价值 387,125,287.50 美元。这代表其持股减少了 3.43%。该交易在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席执行官 August J. Troendle 在 11 月 28 日（星期五）出售了 15,151 股 Medpace 股票。股票以 593.46 美元的平均价格出售，总交易额为 8,991,512.46 美元。交易完成后，首席执行官在公司持有 675,728 股，价值约 401,017,538.88 美元。这代表其持股减少了 2.19%。有关此次出售的更多细节可在官方 SEC 披露中找到。在其他新闻中，首席执行官 August J. Troendle 在 11 月 26 日（星期三）出售了 41,331 股该股票。股票以 606.88 美元的平均价格出售，总交易额为 25,082,957.28 美元。交易完成后，首席执行官在公司持有 690,879 股，价值约 419,280,647.52 美元。这代表其持股减少了 5.64%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。</p>
<h2>分析师设定新的价格目标</h2>
<p>几位股票分析师最近对该公司发布了报告。Truist Financial 在 10 月 27 日（星期一）的研究报告中将 Medpace 的目标价设定为 555.00 美元。Cowen 在 10 月 24 日（星期五）的报告中重申了对 Medpace 股票的 “卖出” 评级。Mizuho 在 10 月 24 日（星期五）将 Medpace 的目标价从 575.00 美元上调至 655.00 美元，并给予该股 “跑赢大盘” 的评级。BMO 资本市场在 11 月 13 日（星期四）对 Medpace 股票进行了覆盖，给予 “市场表现” 评级和 600.00 美元的价格目标。最后，Jefferies 金融集团在 9 月 9 日（星期二）的研究报告中将 Medpace 的价格目标从 400.00 美元上调至 450.00 美元，并给予该股 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，两位给予买入评级，十位给予持有评级，四位给予卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均价格目标为 487.18 美元。</p>
<p><strong>查看我们最新的 MEDP 股票报告</strong></p>
<h2>Medpace 股价下跌 3.7%</h2>
<p>该公司的市值为 156.3 亿美元，市盈率为 38.81，PEG 比率为 2.21，贝塔值为 1.43。该股的 50 日移动平均价格为 565.74 美元，200 日移动平均价格为 450.35 美元。</p>
<p>Medpace (NASDAQ:MEDP - 获取免费报告) 最近在 10 月 22 日（星期三）公布了季度财报。公司报告该季度每股收益为 3.86 美元，超出市场共识预期的 3.50 美元，超出幅度为 0.36 美元。该季度公司收入为 6.599 亿美元，而分析师预期为 6.4049 亿美元。Medpace 的净利润率为 18.36%，股本回报率为 91.88%。与去年同期相比，该季度的收入增长了 23.7%。去年同期，公司每股收益为 3.01 美元。Medpace 已将其 2025 财年的指导目标设定为 14.600-14.860 每股收益。平均而言，卖方分析师预测 Medpace Holdings, Inc.在当前财年将发布 12.29 美元的每股收益。</p>
<h2>Medpace 的机构交易</h2>
<p>几位大型投资者最近调整了对该公司的持股。Quent Capital LLC 在第三季度收购了 Medpace 的新股份，价值约 25,000 美元。Optiver Holding B.V.在第三季度购买了 Medpace 的新头寸，价值约 27,000 美元。Quarry LP 在第三季度收购了 Medpace 的新股份，价值约 35,000 美元。Root Financial Partners LLC 在第三季度购买了 Medpace 的新股份，价值约 38,000 美元。最后，Geneos Wealth Management Inc.在第一季度将其在 Medpace 的持股增加了 64.9%。Geneos Wealth Management Inc.现在持有 94 股该公司的股票，价值 29,000 美元，此前在上个季度又收购了 37 股。目前 77.98% 的股票由机构投资者和对冲基金持有。</p>
<h2>Medpace 公司简介</h2>
<p>(获取免费报告)</p>
<p>Medpace Holdings, Inc.从事为生物技术、制药和医疗器械行业提供外包临床开发服务。其服务包括医学部门、临床试验管理、数据驱动的可行性研究、研究启动、临床监测、监管事务、患者招募和保留、医学写作、生物统计和数据科学、药物警戒、核心实验室、实验室、诊所和质量保证。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Medpace 更好</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>阿里巴巴的大赌注在突破年后能否获利？</li>
<li>什么是 SEC 文件？</li>
<li>什么是股票中的死亡交叉？</li>
<li>大型科技股的对决：HUBS vs. NBIS vs. TEAM</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Medpace 吗？</h2>
<p>在考虑 Medpace 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Medpace 并不在名单上。</p>
<p>虽然 Medpace 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Medpace控股

<p>Medpace 的股价在首席执行官 August J. Troendle 进行内部出售后下跌了 3.7%，他在几笔交易中出售了大量股份。该股最低交易价格为 530.96 美元，交易量显著减少。分析师对该股的评级不一，普遍维持 “持有” 评级，平均目标价为 487.18 美元。Medpace 报告了强劲的季度收益，超出预期，并将 2025 财年的每股收益指导设定在 14.600-14.860 之间</p>

<p>Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report)'s share price traded down 3.7% on Thursday following insider selling activity. The stock traded as low as $530.96 and last traded at $554.93. 157,218 shares traded hands during trading, a decline of 61% from the average session volume of 408,083 shares. The stock had previously closed at $576.49.</p>
<div class="lb-trans"><p>Medpace Holdings, Inc. (NASDAQ:MEDP - 获取免费报告) 的股价在周四因内部人士出售股票而下跌了 3.7%。该股最低交易价为 530.96 美元，最后交易价为 554.93 美元。在交易中，共成交 157,218 股，较 408,083 股的平均交易量下降了 61%。该股此前收盘价为 576.49 美元。</p>
</div><ul>
<li>Can Medpace Stock Keep up this Pace?</li>
</ul>
<div class="lb-trans"><ul>
<li>Medpace 股票能否保持这种速度？</li>
</ul>
</div><p>Specifically, CEO August J. Troendle sold 23,178 shares of the company's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $593.25, for a total value of $13,750,348.50. Following the completion of the sale, the chief executive officer owned 652,550 shares in the company, valued at $387,125,287.50. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 15,151 shares of Medpace stock in a transaction on Friday, November 28th. The shares were sold at an average price of $593.46, for a total transaction of $8,991,512.46. Following the completion of the transaction, the chief executive officer owned 675,728 shares in the company, valued at approximately $401,017,538.88. This represents a 2.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other news, CEO August J. Troendle sold 41,331 shares of the stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $606.88, for a total transaction of $25,082,957.28. Following the completion of the sale, the chief executive officer owned 690,879 shares in the company, valued at approximately $419,280,647.52. This represents a 5.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>具体来说，首席执行官 August J. Troendle 在 12 月 1 日（星期一）出售了 23,178 股公司的股票。股票以 593.25 美元的平均价格出售，总价值为 13,750,348.50 美元。出售完成后，首席执行官在公司持有 652,550 股，价值 387,125,287.50 美元。这代表其持股减少了 3.43%。该交易在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席执行官 August J. Troendle 在 11 月 28 日（星期五）出售了 15,151 股 Medpace 股票。股票以 593.46 美元的平均价格出售，总交易额为 8,991,512.46 美元。交易完成后，首席执行官在公司持有 675,728 股，价值约 401,017,538.88 美元。这代表其持股减少了 2.19%。有关此次出售的更多细节可在官方 SEC 披露中找到。在其他新闻中，首席执行官 August J. Troendle 在 11 月 26 日（星期三）出售了 41,331 股该股票。股票以 606.88 美元的平均价格出售，总交易额为 25,082,957.28 美元。交易完成后，首席执行官在公司持有 690,879 股，价值约 419,280,647.52 美元。这代表其持股减少了 5.64%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities analysts recently issued reports on the company. Truist Financial set a $555.00 price target on Medpace in a research report on Monday, October 27th. Cowen reissued a &#34;sell&#34; rating on shares of Medpace in a report on Friday, October 24th. Mizuho increased their price target on Medpace from $575.00 to $655.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, October 24th. BMO Capital Markets assumed coverage on shares of Medpace in a research report on Thursday, November 13th. They issued a &#34;market perform&#34; rating and a $600.00 price objective on the stock. Finally, Jefferies Financial Group upped their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a &#34;hold&#34; rating in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average price target of $487.18.</p>
<div class="lb-trans"><p>几位股票分析师最近对该公司发布了报告。Truist Financial 在 10 月 27 日（星期一）的研究报告中将 Medpace 的目标价设定为 555.00 美元。Cowen 在 10 月 24 日（星期五）的报告中重申了对 Medpace 股票的 “卖出” 评级。Mizuho 在 10 月 24 日（星期五）将 Medpace 的目标价从 575.00 美元上调至 655.00 美元，并给予该股 “跑赢大盘” 的评级。BMO 资本市场在 11 月 13 日（星期四）对 Medpace 股票进行了覆盖，给予 “市场表现” 评级和 600.00 美元的价格目标。最后，Jefferies 金融集团在 9 月 9 日（星期二）的研究报告中将 Medpace 的价格目标从 400.00 美元上调至 450.00 美元，并给予该股 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，两位给予买入评级，十位给予持有评级，四位给予卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，平均价格目标为 487.18 美元。</p>
</div><p><strong>View Our Latest Stock Report on MEDP</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MEDP 股票报告</strong></p>
</div><h2>Medpace Trading Down 3.7%</h2>
<div class="lb-trans"><h2>Medpace 股价下跌 3.7%</h2>
</div><p>The firm has a market capitalization of $15.63 billion, a price-to-earnings ratio of 38.81, a PEG ratio of 2.21 and a beta of 1.43. The stock's 50 day moving average price is $565.74 and its two-hundred day moving average price is $450.35.</p>
<div class="lb-trans"><p>该公司的市值为 156.3 亿美元，市盈率为 38.81，PEG 比率为 2.21，贝塔值为 1.43。该股的 50 日移动平均价格为 565.74 美元，200 日移动平均价格为 450.35 美元。</p>
</div><p>Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analysts' expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Medpace (NASDAQ:MEDP - 获取免费报告) 最近在 10 月 22 日（星期三）公布了季度财报。公司报告该季度每股收益为 3.86 美元，超出市场共识预期的 3.50 美元，超出幅度为 0.36 美元。该季度公司收入为 6.599 亿美元，而分析师预期为 6.4049 亿美元。Medpace 的净利润率为 18.36%，股本回报率为 91.88%。与去年同期相比，该季度的收入增长了 23.7%。去年同期，公司每股收益为 3.01 美元。Medpace 已将其 2025 财年的指导目标设定为 14.600-14.860 每股收益。平均而言，卖方分析师预测 Medpace Holdings, Inc.在当前财年将发布 12.29 美元的每股收益。</p>
</div><h2>Institutional Trading of Medpace</h2>
<div class="lb-trans"><h2>Medpace 的机构交易</h2>
</div><p>Several large investors have recently modified their holdings of the business. Quent Capital LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace during the third quarter valued at approximately $27,000. Quarry LP acquired a new stake in Medpace during the third quarter worth approximately $35,000. Root Financial Partners LLC purchased a new stake in Medpace in the 3rd quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几位大型投资者最近调整了对该公司的持股。Quent Capital LLC 在第三季度收购了 Medpace 的新股份，价值约 25,000 美元。Optiver Holding B.V.在第三季度购买了 Medpace 的新头寸，价值约 27,000 美元。Quarry LP 在第三季度收购了 Medpace 的新股份，价值约 35,000 美元。Root Financial Partners LLC 在第三季度购买了 Medpace 的新股份，价值约 38,000 美元。最后，Geneos Wealth Management Inc.在第一季度将其在 Medpace 的持股增加了 64.9%。Geneos Wealth Management Inc.现在持有 94 股该公司的股票，价值 29,000 美元，此前在上个季度又收购了 37 股。目前 77.98% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Medpace Company Profile</h2>
<div class="lb-trans"><h2>Medpace 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.</p>
<div class="lb-trans"><p>Medpace Holdings, Inc.从事为生物技术、制药和医疗器械行业提供外包临床开发服务。其服务包括医学部门、临床试验管理、数据驱动的可行性研究、研究启动、临床监测、监管事务、患者招募和保留、医学写作、生物统计和数据科学、药物警戒、核心实验室、实验室、诊所和质量保证。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Medpace</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>Can Alibaba’s Big Bets Pay Off After a Breakout Year?</li>
<li>What is a SEC Filing?</li>
<li>How Accenture's OpenAI Partnership Turns AI Hype Into Profits</li>
<li>What is a Death Cross in Stocks?</li>
<li>Battle of the Big-Upside Tech Names: HUBS vs. NBIS vs. TEAM</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Medpace 更好</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>阿里巴巴的大赌注在突破年后能否获利？</li>
<li>什么是 SEC 文件？</li>
<li>什么是股票中的死亡交叉？</li>
<li>大型科技股的对决：HUBS vs. NBIS vs. TEAM</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Medpace Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Medpace 吗？</h2>
</div><p>Before you consider Medpace, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Medpace 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Medpace 并不在名单上。</p>
</div><p>While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Medpace 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Medpace（NASDAQ:MEDP）股价在内部人士出售股票后下跌 3.7%